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ing were independent predictors of a high Gensini score. 
There were no differences in terms of presence and severity 
of baldness in subjects with and without adequate collateral 
development.
Conclusions There was no relation between presence, se-
verity and age of occurrence of male pattern baldness and 
Gensini and Rentrop scores, which are important measures 
of presence and severity of CAD.
Keywords Baldness · Alopecia · Coronary artery 
disease · Atherosclerosis · Gensini · Rentrop
Introduction
Coronary artery disease (CAD) is the leading cause of mor-
bidity and mortality throughout the world [1, 2]. Classical 
CAD risk factors are not enough to explain all coronary 
events. Therefore, researchers are searching for potential 
novel risk factors for CAD.
Male pattern baldness, also called androgenetic alopecia, 
is responsible for the majority of hair loss in male individu-
als [3–5]. It generally starts at the second or third decade 
and is characterised by varying degrees of thinning/hair loss 
primarily at the frontal area and vertex of the scalp.
Several epidemiological studies have shown an associa-
tion between androgenetic alopecia and CAD [6–10]. Among 
these, the Framingham Heart Study revealed an association 
between progression of hair loss during adulthood and CAD 
in male individuals, although there was no relationship with 
the extent of baldness [7]. In a case-control study, Lesko 
et al. [9] reported that vertex baldness was associated with 
threefold higher risk of myocardial infarction among men 
younger than 55 years. Several other studies reported the 
presence of an association between androgenetic alopecia 
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and CAD [11–13]. However, results of several other studies 
argue against this relationship [14, 15].
Clarifying the potential relationship between androge-
netic alopecia and CAD might help to better understand the 
pathophysiology of coronary heart disease. Although several 
epidemiological studies have shown an association between 
male pattern baldness and atherosclerosis, it has never been 
studied by investigating angiographic presence and severity 
of CAD. We therefore aimed to shed light on this issue by 
investigating whether there is an association between male 
pattern baldness and angiographic CAD severity and col-
lateral development.
Material and methods
Study population and protocol
The study complies with the principles outlined in the Dec-
laration of Helsinki. The study was approved by the local 
ethics committee, and all participants gave written informed 
consent before participating. Patients scheduled for an elec-
tive coronary arteriogram in the Cardiology Department of 
Gaziantep University Hospital were invited to participate.
Demographic data on the study population including age, 
sex, height, weight, history of diabetes mellitus, hyperten-
sion, smoking status, family history of CAD, lipid param-
eters and creatinine levels were recorded. Before coronary 
arteriogram, the presence and severity of hair loss was 
recorded according to the criteria mentioned later in the text. 
Severity of CAD was determined according to the Gensini 
score and collateral flow was graded according to the Rent-
rop score. Exclusion criteria were female sex, history of 
coronary artery bypass surgery, history of acute coronary 
syndrome in the past 4 weeks, other types of alopecia and 
patients with known hormonal problems.
Coronary arteriogram
Coronary arteriogram was performed via the femoral, 
radial or brachial artery using Judkins technique (Integris 
H 5000, Philips Medical Systems, the Netherlands). Coro-
nary artery stenosis severity (Gensini and Rentrop scores) 
was estimated visually by two independent observers who 
were blinded to clinical information on the patients. Then 
the mean of the two measures was calculated.
Evaluation of coronary artery disease severity
Coronary arteries were considered to be normal (0: no ste-
nosis), obstructed (25, 50, 75, 90 or 99 % stenosis) or 100 % 
occluded, according to the maximum obstruction that was 
observed in any projection. The severity of coronary ath-
erosclerosis was classified according to the Gensini score, 
which grades narrowing of the lumen as 1 for 1–25 % ste-
nosis, 2 for 26–50 %, 4 for 51–75 %, 8 for 76–90 %, 16 for 
91–99 % and 32 for total occlusion [16]. This score was 
multiplied by a factor that accounted for the importance 
of a lesion’s position in the coronary arterial tree: 5 for the 
left main coronary artery; 2.5 for the proximal left anterior 
descending coronary artery or proximal circumflex artery; 
1.5 for the mid left anterior descending coronary artery; 1 
for the proximal right coronary artery, distal left anterior 
descending coronary artery, obtuse marginal artery or pos-
terior lateral artery; and 0.5 for other stenoses. The severity 
of disease was expressed as the sum of the scores for the 
individual lesions. By definition, a Gensini score of 20 or 
more was considered to be severe CAD.
Evaluation of collateral development
Collateral vessels were graded according to the Rentrop 
classification: 0: no filling of any collateral vessels, 1: fill-
ing of side branches of the artery to be perfused by collateral 
vessels without visualisation of the epicardial segment; 2: 
partial filling of the epicardial artery by collateral vessels; 
and 3: complete filling of the epicardial artery by collateral 
vessels [17]. By definition, a Rentrop score of 2 or more was 
accepted as well-developed collaterals.
Classification of hair loss (baldness scale)
We used the modified Hamilton grading system, as it was 
used by the majority of the studies: Grade 1: no hair loss; 
Grade 2: frontal baldness only; Grade 3: mild vertex bald-
ness; Grade 4: moderate vertex baldness and Grade 5: severe 
vertex baldness as previously described [12, 18]. Each 
investigator had a chart illustrating these five different hair 
types, as depicted by Lotufo et al. [12] and decided to which 
grade the individual patient’s hair status fits best. Addition-
ally, investigators asked each participant which category 
best describes his hair status when he was 35 years old.
Statistical analysis
According to the power calculation, to provide 95 % power 
at 5 % significance to detect a 4 % mean absolute difference 
in baldness and Gensini score, 306 subjects were neces-
sary. To provide 80 % power at 5 % significance to detect 
a 4 % mean absolute difference in baldness and Rentrop 
score, 149 subjects were necessary. Continuous data were 
expressed as mean ± standard deviation, while categorical 
data were presented as number or percentage of patients. 
Chi-square test was used for comparison of categorical vari-
ables, while the Mann–Whitney U test was used to compare 
continuous variables. Correlation analyses were performed 
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of presence and severity of baldness, hair status at the age 
of 35, demographic characteristics and laboratory findings 
in subjects with (Rentrop score ≥ 2) and without (Rentrop 
score 0 or 1) adequate collateral development. Additionally, 
the rate of smoking, presence of diabetes, hypertension and 
family history of CAD were similar in subjects with and 
without adequate collateral development.
Of 511 patients, 59 had normal coronary arteries (zero-
vessel disease), 171 had one-vessel disease, 176 had two-
vessel disease and 105 had triple-vessel disease. The mean 
number of diseased vessels was higher in bald subjects when 
compared with their non-bald counterparts (1.71 ± 0.9 vs. 
1.44 ± 0.9; p = 0.004). The number of diseased vessels corre-
lated with the severity of baldness (r = 0.125; p = 0.005). The 
mean number of diseased vessels was lower in the group 
with adequate collateral development when compared with 
those without adequate collateral development (2.47 ± 0.5 
with Pearson’s test. Multivariate logistic regression analy-
sis (backward) was performed to determine the indepen-
dent predictors of a high Gensini score. A value of p < 0.05 
was considered statistically significant. All analyses were 
carried out with SPSS version 15.0 software for Windows 
(SPSS Inc., Chicago, Illinois, USA).
Results
A total of 511 male patients (mean age: 58.6; range: 33–84) 
were included in the study. Gensini score was available in 
511 patients, whereas the Rentrop score was available in 
136 patients. Table 1 presents the characteristics of the study 
population.
Comparison of demographic, clinical and laboratory 
characteristics of the subjects according to Gensini score 
is expressed in Table 2. Those with a higher Gensini score 
(≥ 20) were older, had a higher level of triglycerides and 
androgenetic alopecia was more common among them. The 
hair status at the age of 35 was similar between the groups 
with high and low Gensini scores. Additionally, the rest 
of the laboratory results and demographic characteristics 
were similar between the groups with high and low Gen-
sini scores. When we compared bald (modified Hamilton 
score ≥ 2) and non-bald (modified Hamilton score = 1) sub-
jects, bald patients had a higher Gensini score (44.2 ± 42.1 
vs. 33.0 ± 35.3; p = 0.003). Smoking rate was higher in the 
group with higher Gensini scores (p = 0.002). There were no 
differences in terms of presence of diabetes, hypertension 
and family history of CAD between the groups with high 
and low Gensini scores.
Comparison of demographic, clinical and laboratory 
characteristics of the subjects according to the Rentrop score 
is expressed in Table 3. There were no differences in terms 
Table 1 Characteristics of the study population
N
Age 511 58.6 ± 12.0
Hypertension (%) 511 182 (35.7)
Diabetes (%) 511 106 (20.9)
Smoking (%) 511 330 (64.6)
Family history (%) 511 190 (37.2)
Baldness scale 511 2.84 ± 1.54
Gensini score 511 41.3 ± 40.3
Rentrop score 136 1.84 ± 1.09
Body mass index (kg/m2) 509 27.1 ± 4.4
Creatinine (mg/dl) 478 1.02 ± 0.94
Low-density lipoprotein (mg/dl) 419 111.2 ± 33.5
High-density lipoprotein (mg/dl) 419 35.5 ± 15.9
Total cholesterol (mg/dl) 419 176.0 ± 42.0
Triglyceride (mg/dl) 419 173.3 ± 128.0
Data are expressed as mean ± standard deviation or percentages
Table 2 Comparison of demographic, clinical and laboratory charac-
teristics of the subjects according to Gensini score





Age 196 56.3 ± 12.2 315 60.1 ± 11.7 0.001
Baldness scale 196 2.63 ± 1.5 314 2.97 ± 1.5 0.016
Baldness scale at 
age 35
170 1.58 ± 0.9 293 1.52 ± 0.9 0.4
Creatinine, mg/dl 179 1.03 ± 1.17 295 1.01 ± 0.78 0.8
Triglycerides, mg/dl 161 154.5 ± 81 263 185.5 ± 149 0.006
HDL, mg/dl 152 36.7 ± 9.9 263 34.7 ± 18.5 0.1
LDL, mg/dl 158 112 ± 30.8 264 110.7 ± 35.1 0.7
Total cholesterol, 
mg/dl
158 175.8 ± 37.6 264 176.2 ± 44.7 0.6
BMI, kg/m2 195 27 ± 4.2 310 27.4 ± 4.3 0.2
Data are expressed as mean ± standard deviation or as number of 
patients
HDL high-density lipoprotein, LDL low-density lipoprotein, BMI 
body mass index
Table 3 Comparison of demographic, clinical and laboratory charac-
teristics of the subjects according to Rentrop score
Parameter N Rentrop < 2 N Rentrop ≥ 2 p Value
Age 42 58.2 ± 12.6 94 60.6 ± 12.1 0.3
Baldness scale 42 3 ± 1.4 94 2.9 ± 1.4 0.7
Baldness scale at 
age 35
42 1.67 ± 1 94 1.55 ± 1 0.5
Creatinine, mg/dl 42 0.98 ± 0.38 85 0.97 ± 0.28 0.8
Triglycerides, mg/dl 35 195.5 ± 142.4 77 194.5 ± 158.3 0.9
HDL, mg/dl 35 41.5 ± 45.5 77 32.5 ± 9.2 0.2
LDL, mg/dl 35 111.1 ± 33.9 78 110.7 ± 41.6 0.9
Total cholesterol, 
mg/dl
35 176.3 ± 31.9 77 174.2 ± 55.2 0.8
BMI, kg/m2 42 26.9 ± 4.2 90 27.4 ± 3.7 0.5
Data are expressed as mean ± standard deviation or as number of 
patients
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erosclerosis risk factors such as hypertension, dislipidaemia, 
smoking, hyperinsulinaemia/insulin resistance, metabolic 
syndrome and chronic inflammation [22–24]. Third, it has 
been proposed that the two conditions might share a similar 
pattern of inheritance [12, 25].
In 1972, Cotton et al. [6] for the first time reported an 
association between CAD and baldness. They found bald-
ness as a CAD risk factor in 91 patients with overt CAD. 
However, in 1978, Halim et al. [14] reported that patients 
with myocardial infarction had no increase in male pattern 
alopecia. In 1979, Cooke [26] reported that there was no 
association between CAD and either male pattern alopecia 
or premature male pattern alopecia in 478 male Caucasian 
hospital inpatients. In 1993, in a case-control study, Lesko 
et al. [9] reported that vertex baldness (threefold higher risk 
of myocardial infarction) but not frontal baldness was asso-
ciated with myocardial infarction among men younger than 
55 years. In the Framingham Heart Study, 30-year follow-
up revealed that progression of hair loss during adulthood 
but not extent of baldness was associated with CAD in men 
[7]. Additionally, the First National Health and Nutrition 
Examination Survey reported an association between severe 
baldness and CAD mortality in men younger than 55 years, 
but not among older men [8]. In two recent studies, Sharma 
et al. reported that early-onset androgenetic alopecia in male 
individuals (less than 40 and 45 years old, respectively) is 
independently associated with CAD [27, 28]. In contrast, 
in 2007, Shahar et al. [15] investigated the association of 
androgenetic alopecia with CAD in 5000 men aged 52–75 
years, of whom 767 had a history of myocardial infarction 
and concluded that male pattern baldness cannot be used 
as a risk factor for myocardial infarction or asymptomatic 
atherosclerosis.
To date, there are no other studies in the literature inves-
tigating the association between androgenetic alopecia and 
angiographic CAD severity and collateral development; 
therefore, we cannot make a direct comparison with pub-
lished data. However, our results are in agreement with 
those of Shahar et al. We were not able to detect any relation 
between presence, severity and age of occurrence of male 
pattern baldness and Gensini and Rentrop scores, which 
are important measures of presence and severity of CAD. 
In our study, although subjects with higher Gensini scores 
had more frequent and severe baldness, they were older 
than the group with lower Gensini scores. And after adjust-
ing for age, presence and severity of baldness lost its value 
in predicting severity of CAD. Additionally, there were no 
differences in terms of presence and severity of baldness 
in subjects with and without adequate collateral develop-
ment. Thus, the previously reported association between 
CAD and androgenetic alopecia was not confirmed in our 
angiographic study.
vs. 2.69 ± 0.4; p = 0.028). The number of diseased vessels 
was inversely correlated with Rentrop score (r = − 0.226; 
p = 0.008).
In univariate analysis, age more than 60, body mass 
index more than 30, smoking and baldness were among the 
predictors of a high Gensini score. In multivariate analysis, 
only age more than 60 (p < 0.001; odds ratio 2.590; 95 % 
confidence interval 1.637–4.098), smoking (p < 0.001; odds 
ratio 2.385; 95 % confidence interval 1.496–3.802) and 
body mass index more than 30 (p = 0.012; odds ratio 1.937; 
95 % confidence interval:1.154–3.252) were independent 
predictors of a high Gensini score (Table 4). After adjusting 
for age, presence and severity of baldness was not an inde-
pendent predictor of a high Gensini score.
Discussion
In the present study, we aimed to investigate whether there 
is an association between male pattern baldness and angio-
graphic CAD severity and collateral development, which 
has not been reported previously. According to our findings, 
although subjects with higher Gensini scores had more fre-
quent and severe baldness, they were older than the group 
with lower Gensini scores. After adjusting for age, pres-
ence and severity of baldness lost its value in predicting the 
severity of CAD. Additionally, there were no differences in 
terms of presence and severity of baldness in subjects with 
and without adequate collateral development.
Because CAD is the leading cause of morbidity and 
mortality worldwide, researchers aim to investigate poten-
tial novel risk factors or associated conditions which might 
enable the early detection of CAD. Male pattern baldness 
is androgen-dependent miniaturisation and loss of fron-
tal and/or vertical hair. It generally starts at the second or 
third decades and effects almost half of middle-aged men. 
Therefore, it is quite reasonable that investigators are trying 
to clarify the presence and extent of a potential interaction 
between CAD and male pattern baldness.
Although the exact reason for the association between 
baldness and CAD is unclear, several mechanisms have 
been proposed. First, elevated androgen levels and increased 
peripheral sensitivity to androgens have been reported, both 
in subjects with androgenetic alopecia and CAD [19–21]. 
Second, it has been suggested that they have common ath-
Table 4 Independent predictors of Gensini score > 20 (multivariate 
logistic regression analysis)
Variable Odds ratio 95 % Confidence interval
Age > 60 2.590 1.637–4.098
Smoking 2.385 1.496–3.802
BMI > 30 kg/m2 1.937 1.154–3.252
BMI body mass index
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sectional study; therefore, it would provide more valuable 
information if we were able to follow-up the study popula-
tion, especially to draw conclusions about clinical coronary 
events. Third, we asked each participant which category 
best describes his hair status when he was 35 years old. This 
might cause recall bias. Fortunately, it was not our primary 
hypothesis.
Conclusion
In summary, although the majority of studies reported an 
association between androgenetic alopecia and CAD, we 
were not able to detect any relation between presence, 
severity and age of occurrence of male pattern baldness and 
Gensini and Rentrop scores, which are important measures 
of presence and severity of CAD. The potential interaction 
of male pattern baldness with CAD warrants large-scale 
prospective studies.
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